Arrhythmogenic Cardiomyopathy: Pharmacologic Management

Mark S. Link; N. A Mark Estes

doi:10.1016/j.ccep.2011.02.005

Arrhythmogenic Cardiomyopathy: Pharmacologic Management

Research output: Contribution to journal › Review article › peer-review

Abstract

Pharmacologic management of disease is performed for specific reasons, which include reducing symptoms, preventing disease progression, and preventing mortality. In arrhythmogenic cardiomyopathy (AC), there are no randomized clinical trial data on pharmacologic management, and little data overall on the use of drugs in this condition. This article discusses the role of pharmacology in AC to prevent symptoms, limit progression of disease, and prolong life.

Original language	English (US)
Pages (from-to)	293-298
Number of pages	6
Journal	Cardiac Electrophysiology Clinics
Volume	3
Issue number	2
DOIs	https://doi.org/10.1016/j.ccep.2011.02.005
State	Published - Jun 2011

Keywords

Antiarrhythmic agents
Arrhythmogenic right ventricular cardiomyopathy/dysplasia
Pharmacologic management
Therapy
β-Blocker

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1016/j.ccep.2011.02.005

Cite this

@article{c335f3fe274241cf84a2742e1a1c4e4a,

title = "Arrhythmogenic Cardiomyopathy: Pharmacologic Management",

abstract = "Pharmacologic management of disease is performed for specific reasons, which include reducing symptoms, preventing disease progression, and preventing mortality. In arrhythmogenic cardiomyopathy (AC), there are no randomized clinical trial data on pharmacologic management, and little data overall on the use of drugs in this condition. This article discusses the role of pharmacology in AC to prevent symptoms, limit progression of disease, and prolong life.",

keywords = "Antiarrhythmic agents, Arrhythmogenic right ventricular cardiomyopathy/dysplasia, Pharmacologic management, Therapy, β-Blocker",

author = "Link, {Mark S.} and Estes, {N. A Mark}",

year = "2011",

month = jun,

doi = "10.1016/j.ccep.2011.02.005",

language = "English (US)",

volume = "3",

pages = "293--298",

journal = "Cardiac Electrophysiology Clinics",

issn = "1877-9182",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Arrhythmogenic Cardiomyopathy

T2 - Pharmacologic Management

AU - Link, Mark S.

AU - Estes, N. A Mark

PY - 2011/6

Y1 - 2011/6

N2 - Pharmacologic management of disease is performed for specific reasons, which include reducing symptoms, preventing disease progression, and preventing mortality. In arrhythmogenic cardiomyopathy (AC), there are no randomized clinical trial data on pharmacologic management, and little data overall on the use of drugs in this condition. This article discusses the role of pharmacology in AC to prevent symptoms, limit progression of disease, and prolong life.

AB - Pharmacologic management of disease is performed for specific reasons, which include reducing symptoms, preventing disease progression, and preventing mortality. In arrhythmogenic cardiomyopathy (AC), there are no randomized clinical trial data on pharmacologic management, and little data overall on the use of drugs in this condition. This article discusses the role of pharmacology in AC to prevent symptoms, limit progression of disease, and prolong life.

KW - Antiarrhythmic agents

KW - Arrhythmogenic right ventricular cardiomyopathy/dysplasia

KW - Pharmacologic management

KW - Therapy

KW - β-Blocker

UR - http://www.scopus.com/inward/record.url?scp=79954575994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954575994&partnerID=8YFLogxK

U2 - 10.1016/j.ccep.2011.02.005

DO - 10.1016/j.ccep.2011.02.005

M3 - Review article

AN - SCOPUS:79954575994

SN - 1877-9182

VL - 3

SP - 293

EP - 298

JO - Cardiac Electrophysiology Clinics

JF - Cardiac Electrophysiology Clinics

IS - 2

ER -

Arrhythmogenic Cardiomyopathy: Pharmacologic Management

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this